13 July 2012 - Ampio Pharmaceuticals Inc (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs, licensing distribution of these drugs and developing additional new drugs, has announced today the pricing of its previously announced underwritten public offering of 4,615,400 shares of its common stock.

The common stock is offered at a price to the public at USD3.25 per share. The company will generate USD15m from the deal.

The offering is likely to close on or around July 18, 2012, subject to customary closing conditions. The joint book-running managers for the offering are Aegis Capital Corp and Fordham Financial Management Inc.